The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Chemotherapy Drugs for Neuroblastoma Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Chemotherapy Drugs for Neuroblastoma Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1751700

No of Pages : 103

Ask Your Query

Synopsis

The global Chemotherapy Drugs for Neuroblastoma market size was valued at USD 126.6 million in 2022 and is forecast to a readjusted size of USD 171.1 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

This report is a detailed and comprehensive analysis for global Chemotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Chemotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Chemotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Chemotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
  • Global Chemotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Chemotherapy Drugs for Neuroblastoma
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace

This report profiles key players in the global Chemotherapy Drugs for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals and Qilu Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Chemotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Cyclophosphamide
  • Cisplatin or Carboplatin
  • Vincristine
  • Doxorubicin (Adriamycin)
  • Etoposide
  • Other

Market segment by Application

  • Hospital
  • Clinic
  • Other

Major players covered

  • Baxter Healthcare
  • Ingenus Pharmaceuticals
  • ANI Pharmaceuticals
  • Teva Pharmaceuticals
  • Qilu Pharmaceutical
  • Pfizer
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Accord Healthcare
  • Viatris

Market segment by region, regional analysis covers

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Chemotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Chemotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Chemotherapy Drugs for Neuroblastoma from 2018 to 2023.
Chapter 3, the Chemotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chemotherapy Drugs for Neuroblastoma breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Chemotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Chemotherapy Drugs for Neuroblastoma.
Chapter 14 and 15, to describe Chemotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Chemotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Cyclophosphamide
1.3.3 Cisplatin or Carboplatin
1.3.4 Vincristine
1.3.5 Doxorubicin (Adriamycin)
1.3.6 Etoposide
1.3.7 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Chemotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Chemotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Baxter Healthcare
2.1.1 Baxter Healthcare Details
2.1.2 Baxter Healthcare Major Business
2.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
2.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Baxter Healthcare Recent Developments/Updates
2.2 Ingenus Pharmaceuticals
2.2.1 Ingenus Pharmaceuticals Details
2.2.2 Ingenus Pharmaceuticals Major Business
2.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.3 ANI Pharmaceuticals
2.3.1 ANI Pharmaceuticals Details
2.3.2 ANI Pharmaceuticals Major Business
2.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 ANI Pharmaceuticals Recent Developments/Updates
2.4 Teva Pharmaceuticals
2.4.1 Teva Pharmaceuticals Details
2.4.2 Teva Pharmaceuticals Major Business
2.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Teva Pharmaceuticals Recent Developments/Updates
2.5 Qilu Pharmaceutical
2.5.1 Qilu Pharmaceutical Details
2.5.2 Qilu Pharmaceutical Major Business
2.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Qilu Pharmaceutical Recent Developments/Updates
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments/Updates
2.7 Hikma Pharmaceuticals
2.7.1 Hikma Pharmaceuticals Details
2.7.2 Hikma Pharmaceuticals Major Business
2.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
2.8 Fresenius Kabi
2.8.1 Fresenius Kabi Details
2.8.2 Fresenius Kabi Major Business
2.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Fresenius Kabi Recent Developments/Updates
2.9 Accord Healthcare
2.9.1 Accord Healthcare Details
2.9.2 Accord Healthcare Major Business
2.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Accord Healthcare Recent Developments/Updates
2.10 Viatris
2.10.1 Viatris Details
2.10.2 Viatris Major Business
2.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
2.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Viatris Recent Developments/Updates
3 Competitive Environment: Chemotherapy Drugs for Neuroblastoma by Manufacturer
3.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Chemotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Chemotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Chemotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Chemotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Chemotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Chemotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Chemotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 North America
7.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Chemotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Chemotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Chemotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Chemotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Chemotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Chemotherapy Drugs for Neuroblastoma Market Drivers
12.2 Chemotherapy Drugs for Neuroblastoma Market Restraints
12.3 Chemotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Chemotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Chemotherapy Drugs for Neuroblastoma
13.3 Chemotherapy Drugs for Neuroblastoma Production Process
13.4 Chemotherapy Drugs for Neuroblastoma Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Chemotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Chemotherapy Drugs for Neuroblastoma Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock